Objectives and background: Oral squamous cell carcinoma (OSCC) is a highly malignant disease with an increasing incidence. The need to improve therapeutic strategies for patients affected by OSCC is an urgent challenge. Currently, the advent of immunotherapy represents an important step toward this aim. Programmed cell death-ligand 1 (PD-L1), a membrane protein that can be expressed on tumor and inflammatory cells is a key biomarker whose expression is determined by means of immunohistochemistry and is necessary for selecting patients for immunotherapy. Methods: In this study, we review the methods of PD-L1 assessment and outcomes achieved with immunotherapy in the treatment of OSCC patients. Results: Based on a meta-analysis we demonstrate a lack of prognostic significance of PD-L1 in OSCC. Conclusions: We also highlight unresolved issues including difficulties in standardizing PD-L1 evaluation and discuss future opportunities such as leveraging digital pathology.

PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside / Nocini, Riccardo; Vianini, Matteo; Girolami, Ilaria; Calabrese, Luca; Scarpa, Aldo; Martini, Maurizio; Morbini, Patrizia; Marletta, Stefano; Brunelli, Matteo; Molteni, Gabriele; Parwani, Anil; Pantanowitz, Liron; Eccher, Albino. - In: CLINICAL AND EXPERIMENTAL DENTAL RESEARCH. - ISSN 2057-4347. - 8:3(2022), pp. 690-698. [10.1002/cre2.590]

PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside

Molteni, Gabriele;Eccher, Albino
2022

Abstract

Objectives and background: Oral squamous cell carcinoma (OSCC) is a highly malignant disease with an increasing incidence. The need to improve therapeutic strategies for patients affected by OSCC is an urgent challenge. Currently, the advent of immunotherapy represents an important step toward this aim. Programmed cell death-ligand 1 (PD-L1), a membrane protein that can be expressed on tumor and inflammatory cells is a key biomarker whose expression is determined by means of immunohistochemistry and is necessary for selecting patients for immunotherapy. Methods: In this study, we review the methods of PD-L1 assessment and outcomes achieved with immunotherapy in the treatment of OSCC patients. Results: Based on a meta-analysis we demonstrate a lack of prognostic significance of PD-L1 in OSCC. Conclusions: We also highlight unresolved issues including difficulties in standardizing PD-L1 evaluation and discuss future opportunities such as leveraging digital pathology.
2022
8
3
690
698
PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside / Nocini, Riccardo; Vianini, Matteo; Girolami, Ilaria; Calabrese, Luca; Scarpa, Aldo; Martini, Maurizio; Morbini, Patrizia; Marletta, Stefano; Brunelli, Matteo; Molteni, Gabriele; Parwani, Anil; Pantanowitz, Liron; Eccher, Albino. - In: CLINICAL AND EXPERIMENTAL DENTAL RESEARCH. - ISSN 2057-4347. - 8:3(2022), pp. 690-698. [10.1002/cre2.590]
Nocini, Riccardo; Vianini, Matteo; Girolami, Ilaria; Calabrese, Luca; Scarpa, Aldo; Martini, Maurizio; Morbini, Patrizia; Marletta, Stefano; Brunelli, Matteo; Molteni, Gabriele; Parwani, Anil; Pantanowitz, Liron; Eccher, Albino
File in questo prodotto:
File Dimensione Formato  
Clinical Exp Dental Res - 2022 - Nocini.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 2.7 MB
Formato Adobe PDF
2.7 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1317427
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
social impact